Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2002

View Archived Issues

Positive phase I results for AGI-1096 in prevention of transplant rejection

Amgen files sBLA for Enbrel for improvement of physical function in RA

Theratechnologies adds GLP-1 program to portfolio, signs development agreement with Alza

Final phase I results for Antrin phototherapy in coronary artery disease

Phase I/II interim analysis of Targretin in chronic severe hand dermatitis

Cholestagel MAA filed for primary hypercholesterolemia

NicOx signs exclusive agreement with AstraZeneca for AZD-3582 and other CINODs in Japan

GPI-1485 shows neuroprotective activity in preclinical models of postprostatectomy ED

ISV-401 safe and effective in acute bacterial conjunctivitis

Monoclonal antibodies targeting human BST2

Anti-MRSA cephalosporin and prodrug presented at ICAAC meeting

Potent and broad-spectrum antifungal activity in a series of thiotriazolones

Quinolone-linked oxazolidinones investigated at Morphochem

Korean researchers identify potent parenteral cephalosporin for resistant infections

Phase III interim findings for protease inhibitor GW-433908 discussed in San Diego

Marketing approval granted for first aldosterone blocker in high blood pressure

MGI Pharma/Helsinn seek FDA approval for new CINV therapy

Thrombopoietin agonists prepared and tested at Shionogi

Novartis designs new DPP-IV inhibitors for diabetes mellitus

Toyama researchers identify novel agents for cerebral ischemic disorders

Novel immunosuppressants in early development at Sumitomo

Venantius claims mast cell-stabilizing agents for inflammatory disorders

Novel inhibitors of TNF-alpha and/or IL-1beta production described in Sankyo patent

Long-term survival data for Gliadel Wafer in brain cancer

Allovectin-7 update

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...